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in patients with osteogenesis imperfecta
Mirjana Turkalj1,4,10, Vesna Miranović2,3, Rajka Lulić-Jurjević1,4, 
Romana Gjergja Juraški1,4, Dragan Primorac1,4,5,6,7,8,9
Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder, usually caused by dominant mutations of genes coding for 
collagen type I alpha chains, COL1A1/A2. Although skeletal manifestations of OI are most readily observable, cardiopulmonary 
disorders in patients with OI are increasingly recognized as life-threatening but treatable disorders. Unfortunately, the majority of 
patients with moderate to severe types of OI die from or with cardiopulmonary complications. The lungs and the heart are often 
unrecognizable and neglected organs in patients with OI. In monitoring of patients with OI, attention is mostly focused on monitor-
ing long bone and spine deformities, and indirectly deformities of the chest wall, which have consequences on the development of 
lung and the airway diseases. Lung disorder is frequently ignored until breathing problems become severe. An important compo-
nent in patients with OI is obstructive lung disease, sleep disordered breathing, as well as acute and chronic infection often con-
nected with resultant bronchiectasis. In addition to respiratory complications, some patients with OI have serious cardiovascular 
problems, including severe mitral valve prolapse, aortic valve insuffi  ciency and dilation of the aorta, which require cardiac surgery. 
The diagnosis and management of the lung and cardiovascular complications in some patients with OI are quite diffi  cult. In all 
patients with OI, it is important to recognize and monitor respiratory and cardiovascular manifestations in order to prevent further 
progression of any complications.
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INTRODUCTION
Osteogenesis imperfecta (OI), also known as ‘brittle bone 
disease’, is a hereditary disorder of the connective tissue (1, 
2) with a heterogeneous clinical phenotype (3). The severity 
of the disease depends on the eff ect of a specifi c mutation. 
The clinical spectrum of disease phenotypes ranges from 
perinatal mortality to nearly asymptomatic individuals with 
occasional fractures and normal stature (4, 5). Although 
skeletal consequences of OI are well described, less is 
known about other aspects of the disease, especially the 
 eff ect of the disease on the appearance and development 
of respiratory and cardiovascular complications (6, 7).
RESPIRATORY COMPLICATIONS IN PATIENTS 
WITH OSTEOGENESIS IMPERFECTA
People with moderate and severe OI are more vulnerable to 
viral and bacterial respiratory infection of upper and lower 
airways, as well as lung problems, including asthma and 
pneumonia. Patients with OI have a higher risk of death 
from respiratory diseases. In fact, respiratory failure is the 
most common cause of death in people with OI (8-10). A 
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British study that investigated the causes of death of pa-
tients with OI reports 79 deaths between 1980 and 1995 in 
a cohort of 1297 patients with OI (4). McAllion and Paterson 
identified respiratory tract infection as the most common 
cause of death in OI, and found a mean age at death of 6.2 
years in severe OI phenotypes and 63.5 years in milder OI 
phenotypes (8). In a study from Denmark, the authors calcu-
lated the risk and cause of death, and median survival time 
in patients with OI. The median survival time for males with 
OI was 72.4 years, compared to 81.9 in the reference popu-
lation. The median survival time for females with OI was 77.4 
years, compared to 84.5 years in the reference population. 
The authors concluded that patients with OI had a higher 
risk of death from respiratory diseases, gastrointestinal dis-
eases and trauma, and that patients with OI had a higher 
mortality rate throughout their life compared to the general 
population (10). Individuals with moderate forms of OI may 
have near normal life expectancy, but nevertheless, they of-
ten require physical aids to walk and to lead normal life (6). 
Further studies should explore the underlying causes of 
death, the genotype/phenotype association, and the risk of 
death related to respiratory complications.
SUBTYPES OF OSTEOGENESIS IMPERFECTA 
AND RESPIRATORY DISEASES
There are several types of OI and they vary in severity and 
characteristics. The majority of OI cases (possibly 85-90 per-
cent) are caused by dominant mutation in a gene coding 
for type 1 collagen COL1A1 and COL1A2 (11). The molecular 
genetic classifi cation of OI has shown diff erent patterns of 
inheritance and wide variability of clinical severity (12, 13). 
In 2009, the Nosology group of the International Society of 
Skeletal Dysplasias recommended maintaining the Sillence 
classifi cation as the prototypical and universally accepted 
form to classify the degree of OI severity (13, 14). Forlino et 
al. categorized OI into fi ve functional metabolic groups, as 
follows:
a) defects in collagen synthesis, structure or processing;
b) defects in collagen modifi cation;
c) defects in collagen folding and cross-linking;
d) defects in bone mineralization; and
e)  defects in osteoblast development with collagen insuf-
fi ciency (1, 15).
In the past several years, OI has been classifi ed into nine 
 major subtypes based on genetic, radiographic, and clinical 
characteristics. Types I-IV are caused by dominant mutation 
in a gene coding for type 1 collagen (2, 16).
Osteogenesis imperfecta type I is the most common and 
usually the mildest form of OI with normal collagen struc-
ture but less than normal amount, with a low risk of devel-
opment of respiratory complications. Approximately 20 
percent of adults with OI type I develop abnormal sideways 
or front-to-back curvature of the spine (scoliosis or kypho-
sis) and have a risk of developing restrictive lung diseases 
(6, 7, 17).
Type II is the most severe type of OI. Infants with type II OI 
often have underdeveloped lungs and an abnormally small 
upper chest (thorax), which may result in life-threatening 
respiratory insuffi  ciency. Type II frequently causes death at 
birth or shortly after because of respiratory problems. Actu-
ally, infants with type II OI usually die within a few hours or 
days after birth due to respiratory failure related to a small 
thorax and poor thoracic compliance due to multiple rib 
fractures (7-9).
Osteogenesis imperfecta type III is the most severe type in 
children, i.e. those that survive the neonatal period. In OI 
type III, progressive malformation of various bones may re-
sult in short stature, sideways and front-to-back curvature 
of the spine (scoliosis and kyphosis) (6). In some cases, af-
fected children may develop pulmonary insuffi  ciency and 
respiratory problems. Pectus carinatum characterizes pa-
tients with OI type III and alters respiratory muscle coordina-
tion, leading to chest wall and rib cage distortions and an 
ineffi  cient ventilator pattern (1, 6, 18). Development of 
acute respiratory failure secondary to respiratory tract infec-
tion is a common event in patients with OI type III (19, 20). 
In these patients, development of acute respiratory failure 
secondary to respiratory tract infection including bronchi-
tis, bronchiolitis, and pneumonia is usually complicated 
with chronic progressive hypoventilation (7, 18-20).
Individuals with OI type IV have fragile bones that often frac-
ture easily. Fractures are more common before puberty. Af-
fected individuals experience mild to moderate bone malfor-
mation and are usually shorter than average. Aff ected indi-
viduals may develop sideways and front-to-back curvature of 
the spine (scoliosis and kyphosis). OI type IV is characterized 
by lower alterations in respiratory function, but may have 
some lung problems such as restrictive lung disease (11).
Types V and VI are similar to types IV and II OI in terms of 
severity and appearance of respiratory symptoms, however, 
there is predisposition to hyperplastic callus formation and 
hyperosteoid bone (2, 21).
Type VII OI is clinically similar to OI types II and IV but has 
rhizomelia and distinctive feature. Respiratory complica-
tions are frequent and often severe (2, 22).
Types VIII-IX OI resemble severe or lethal types II or III in ap-
pearance and symptoms, including respiratory complica-
tions and death, except for infants having white sclera, se-
vere growth retardation, and extreme skeletal under-miner-
alization (1, 2, 23).
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THE PATHOMECHANISM 
OF RESPIRATORY COMPLICATIONS 
IN PATIENTS WITH OSTEOGENESIS IMPERFECTA
Respiratory manifestations in patients with OI are the result 
of a combination of multiple factors. If the ribs and spine do 
not develop normally, there may be less space for the lungs 
to expand, which is often the case in patients with modera-
te to severe types of OI (1-3). Collagen is also an important 
building block of connective tissue in the lungs. If the col-
lagen synthesis, structure or function is disturbed, the struc-
ture and function of the connective tissue of the lungs are 
also disturbed, especially structures of the interstitium of 
the lung (6, 24). In case studies of OI, the pathology of lung 
hypoplasia is the result of the possible role of mutant colla-
gen. This makes it diffi  cult for aff ected patients with OI to 
get enough oxygen through the alveocapillary barrier be-
cause of the disturbed biomechanics of breathing (25, 26). 
Decreased chest volume, chronic infections and infl amma-
tion in patients with OI lead to the progression of restrictive 
pulmonary disorder (20, 26). In addition, patients with OI 
may have problems on coughing eff ectively to clear away 
mucus (4, 5). Cor pulmonale is considered a late conse-
quence of pulmonary dysfunction in OI (22). Pulmonary 
function data in patients with structurally abnormal colla-
gen but without scoliosis, as well as data from both domi-
nant and recessive animal models are needed to delineate 
the mechanism of pulmonary pathology and development 
of respiratory complications in patients with OI.
PULMONARY FUNCTION IN PATIENTS 
WITH OSTEOGENESIS IMPERFECTA
It is known that patients with OI are characterized by dispro-
portional growth aff ecting predominantly trunk height, col-
lapsing of thoracic vertebrae, more horizontal position of 
the ribs, and sternal deformities (1-3). In patients with OI 
type III or IV, the deformed rib cage (i.e. pectus carinatum, 
more horizontal ribs and more compliant rib cage) alters 
normal action of the intercostal muscles and requires the 
diaphragm to compensate for their reduced contribution to 
tidal volume (20, 25). In these patients, inspiratory paradoxi-
cal inwards motion of the pulmonary rib cage during spon-
taneous breathing in supine position is associated with a 
high level of asynchrony between the three chest wall com-
partments. Individuals with OI and scoliosis >60° have a 
striking decline of pulmonary function (25-27). The pres-
ence of severe restrictive lung disease with minimal scolio-
sis raised the possibility that bone-independent pulmonary 
pathology also contributes substantially to morbidity in 
those with types III and IV OI (26, 27). LoMauro et al. report 
on reduced forced vital capacity and forced expiratory vol-
ume in fi rst second compared to predicted values in both 
OI types III and IV (20). The ventilation was also lower in OI 
patients than in controls because of lower tidal volume. The 
authors showed normal chest wall geometry and function 
in OI type IV patients. OI type III patients were characterized 
by reduced angle at the sternum (pectus carinatum), para-
doxical inspiratory inwards motion of the pulmonary rib 
cage, signifi cant thoracoabdominal asynchronies, and rib 
cage distortions in supine position (20). Still, it is not com-
pletely clear whether and how these features aff ect the 
breathing pattern in OI patients.
RESPIRATORY INFECTIONS IN PATIENTS 
WITH OSTEOGENESIS IMPERFECTA
Patients with OI breathing problems can develop shortness 
of breath, tiredness, insomnia and sleep apnea, and it can 
make the patients more susceptible to respiratory infec-
tions (1-3, 8-10, 29). Restrictive pulmonary disorder, a reduc-
tion of lung capacity, is common in patients with severe OI 
or in those with decreased chest volume, chronic bronchitis 
or asthma, which increases their predisposition to develop-
ment of lower respiratory infection. Respiratory complica-
tions leading to pneumonia or even heart failure represent 
a signifi cant cause of death in people with types II or III OI 
(8-10). Diffi  culties in coughing and expectoration also in-
crease susceptibility to infections in patients with OI. What 
are all the factors that increase the incidence of infections 
and whether the function of the immune system is fully 
preserved in patients with OI remains unknown.
RESPIRATORY COMPLICATIONS IN ADULTS 
WITH OSTEOGENESIS IMPERFECTA
Some individuals with OI type I are so mildly aff ected that 
they are not diagnosed until their teen or adult years. Al-
though often considered a disease with primarily paediatric 
manifestations, more than 25% of lifetime fractures are re-
ported to occur in adulthood (29). In most cases, individuals 
with type I OI seem to experience fewer fractures after pu-
berty, when the bones are no longer growing as quickly. 
Adults with type I OI need to know how the disease can 
manifest during life and what complications can be expect-
ed, including cardiorespiratory complications. General care 
of adults with OI includes measures to preserve bone den-
sity, regular monitoring of hearing and dentition, mainte-
nance of muscle strength through physical therapy, and 
prevention of the development of cardiorespiratory com-
plications (30). Complications of OI in adulthood from spinal 
structural abnormalities such as kyphoscoliosis and basilar 
invagination can cause respiratory insuffi  ciency even in 
those with OI type I. Adults with OI and small stature, scolio-
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sis, or barrel-shaped chest are advised to monitor respirato-
ry function and make pulmonary function test (27). This test 
should be repeated every 2 years depending on the extent 
of scoliosis or chest deformity. All patients with OI should be 
promptly treated for all respiratory infections. Flu shots and 
pneumococcal vaccines are recommended as well (31).
PREVENTION OF RESPIRATORY COMPLICATIONS 
IN PATIENTS WITH OSTEOGENESIS IMPERFECTA
In the prevention of serious respiratory complications, the 
following measures are recommended for patients with OI:
 – immediately treat all respiratory infections, even colds 
and cough;
 – immediately treat any diffi  culties in breathing;
 – regularly monitor respiratory functions by pulmonary 
function testing every year;
 – patients with type III or IV OI, or spine curvature, should 
see a pulmonologist every 1-2 years (32, 33);
 – perform breathing exercises and respiratory physical 
therapy to promote deep breathing. Explain the patient 
how to exercise safely to develop muscle strength and 
lung capacity (34);
 – children and adults should have spine curvature monito-
ring (in some cases, surgery may be necessary);
 – regularly vaccinate (fl u shot and pneumococcal vaccine);
 – prohibit cigarette smoking and avoid exposure to se-
cond-hand smoke;
 – usage of supplemental oxygen and usage of BiPAP (posi-
tive pressure breathing device, can help manage pulmo-
nary function) (35);
 – treat obstructive lung disease, e.g., asthma. Patients with 
OI and chronic asthma need additional regular therapy 
with anti-infl ammatory drugs (32-34);
 – in cooperation with cardiologist, follow-up development 
of cardiorespiratory complications such as aortic root di-
lation and valvular dysfunction. In the assessment of car-
diovascular complications, electrocardiogram and 
echocardiogram should be performed every two years 
(33); and
 – in cooperation with other specialists, get involved in 
multidisciplinary monitoring of patients with OI (35, 36).
CARDIOVASCULAR COMPLICATIONS 
IN PATIENTS WITH OSTEOGENESIS IMPERFECTA
The basic characteristic of OI is defi ciency in the production 
of type I collagen, which is one of the main structural com-
ponents of connective tissues. Therefore, it is an important 
component of myocardium and plays a critical role in the 
structure of blood vessel walls (37, 38). Collagen type I is an 
important constituent in diff erent parts of the cardiovascu-
lar system, including the heart valves, chordae tendinenae, 
fi brous rings of the heart, interventricular septum, aorta, 
and the majority of other arteries (39, 40). Collagen fi bers in 
the ventricular myocardium contribute to tensile stiff ness 
and maintain the architecture of the myocytes (39). Valvular 
regurgitation is a frequently reported cardiovascular disease 
among patients with OI, but most of the current literature 
comprises case reports of small case series.
Cross-sectional studies have reported increased aortic root 
diameter, increased prevalence of diastolic dysfunction and 
valvulopathies in patients with OI, but most of the included 
patients were asymptomatic despite cardiovascular pa-
thology (41). The link between connective tissue disorders 
and cardiovascular pathology is known in disorders includ-
ing Marfan syndrome, Loeys-Dietz syndrome and vascular 
Ehlers-Danlos syndrome. In all three conditions, patients 
have vascular fragility, mostly limited to the aorta in Marfan 
syndrome (42). Taking this in consideration, it would be ex-
pected that the prevalence of cardiovascular manifestations 
in OI is high, but for an irrefutable reason cardiovascular in-
volvement in OI is rare compared with that in Marfan syn-
drome; however, it can be serious when it occurs (43). The 
most dramatic and potentially lethal cardiovascular compli-
cation is aortic root dissection, although valvular disease and 
myocardial dysfunction have also been reported (44, 45).
Radunovic et al. conducted a clinical and echocardiographic 
survey including 99 adults suff ering from OI, with the aim to 
investigate cardiac abnormalities in adult patients with OI. A 
conclusion based on the study results was that increased 
left ventricle end diastolic dimension (LVIDd), left ventricu-
lar (LV) mass, mitral regurgitation, and aortic regurgitation 
(AR) were found in adults with OI (46).
A limited number of studies were conducted on children 
suff ering from OI in order to provide evidence that cardio-
vascular system involvement can occur even without the 
presence of clinical manifestations. A case-control study 
was conducted on 24 children suff ering from OI and 24 
healthy children as a control group in Iran (47). Ejection frac-
tion (EF), shortening fraction (SF), LVIDd, left ventricle end 
systolic dimension (LVIDs), and left ventricular posterior wall 
(LVPWd) were determined and the measurements were 
corrected according to the patient body surface area (BSA). 
LVIDd, LVPWd, aorta annulus, sinotubular junction, ascend-
ing aorta and descending aorta (all parameters corrected 
for BSA) of the OI patients were signifi cantly higher than 
those in the control group. Also, Z score calculated for aorta 
annulus, sinotubular junction, ascending aorta, descending 
aorta and left ventricle dimensions, which were corrected 
for BSA, was <2 for all calculated parameters in the control 
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group, and >2 in patients with OI ranging from 2 to 3.07. In 
general, Z scores >2 and >2.5 were considered aortic dila-
tion in various studies investigating aortic root dilation (48). 
Moreover, cardiovascular eff ects are identifi able in child-
hood even in mild forms of OI (aortic dilation predominant-
ly), as concluded by Rush et al. in their survey of 100 children 
suff ering from OI (49).
The cardiac pathology primarily aff ects the left-sided heart 
valves with aortic insuffi  ciency being the most common le-
sion, followed by mitral regurgitation. Hortop et al. report on 
6.9% incidence of mitral valve prolapse in their cohort of 
109 asymptomatic patients with OI (similar to the 4% to 8% 
incidence found in normal population) (43).
However, Radunovic et al. conducted another study in 2012, 
which showed that all right ventricle (RV) and pulmonary 
artery dimensions indexed by BSA were signifi cantly larger 
in the OI group compared to controls, which means that 
connective tissue disorder in OI includes not only left ven-
tricle and its structures, but the whole myocardium and 
both great arteries (50).
Pulmonary insuffi  ciency is the most common cause of de-
mise in type II OI and aff ects a number of individuals with 
severe type III OI. Both chest wall pathology and severe ky-
phoscoliosis associated with vertebral compression can 
contribute to restrictive lung disease. This may progress to 
pulmonary hypertension and subsequent cor pulmonale, 
requiring oxygen support. Mitral valve prolapse and aortic 
dilatation with or without regurgitation have also been re-
ported (22, 27).
More studies are essential for recommending appropriate 
drug therapy to prevent aortic dilation progress in patients 
suff ering from OI. Some of them have serious cardiovascular 
problems related to their disease, including severe mitral 
valve prolapse, aortic valve insuffi  ciency and dilation of the 
aorta, which require cardiac surgery (51). The friability of the 
tissues in OI can be hazardous before, during and after the 
operation. Potential problems related to anaesthesia in-
clude the following: diffi  cult intubation because of macro-
glossia, short neck and neck immobility, fractures from a 
sphygmomanometer cuff , higher risk of oesophageal tears 
from a transoesophageal echocardiography probe because 
of short and immobile neck, epistaxis from nasogastric tube 
insertion, and dissection of vessels during cannulation. Sur-
gical procedures in OI patients carry a higher risk of bleed-
ing complications, dissection at the cannulation sites, im-
paired wound healing, and wound dehiscence (52).
The mortality rate in patients with OI who require cardiac 
surgery is high. Cardiac surgeons recommend that surgical 
treatment be done gently and surely, having in mind tissue 
friability, which may decrease mortality after cardiac surgery 
in OI patients. A multidisciplinary approach with a planned 
strategy is essential for successful management of patients 
with OI undergoing cardiac surgery. Heightened awareness 
among operating theatre and intensive care staff  is impor-
tant for prevention of complications (51, 52).
CONCLUSION
Children and adults with OI more susceptible to developing 
respiratory complications are those with short stature, sco-
liosis, kyphosis or both (kyphoscoliosis), chest or rib cage 
deformities such as pectus carinatum or pectus excavatum, 
and those with a sedentary lifestyle.
The rule is that the more severe types of OI are more sus-
ceptible to lung or breathing problems. Breathing problems 
can lead to shortness of breath, tiredness, insomnia, sleep 
apnoea, and make the patient more susceptible to infec-
tions such as pneumonia. Restrictive pulmonary disorder, a 
reduction of lung capacity, is common in people with se-
vere OI or anyone who has a decreased chest volume. Pa-
tients with OI have an increased risk of heart disease, and 
actually may have an increased risk of developing valvular 
heart diseases and aortic root dilation in particular. Cardio-
respiratory complications leading to pneumonia or heart 
failure represent a signifi cant cause of death for people with 
OI type II or III. Regular control and prevention of the devel-
opment of cardiorespiratory complications is an imperative 
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S A Ž E T A K
Kardiorespiracijske komplikacije 
u bolesnika s osteogenesis imperfecta
Mirjana Turkalj, Vesna Miranović, Rajka Lulić-Jurjević, Romana Gjergja Juraški, Dragan Primorac
Osteogenesis imperfecta (OI) je nasljedna bolest vezivnog tkiva koja je najčešće uzrokovana dominantnim mutacijama gena koji 
kodiraju alfa lance kolagena tip I, COL1A1/A2. Iako se su skeletne manifestacije najuočljivije, srčanoplućne bolesti u bolesnika s OI sve 
se više prepoznaju kao za život opasne bolesti koje se mogu liječiti. Nažalost, većina bolesnika s umjerenim do teškim tipovima OI 
umire zbog srčanoplućnih komplikacija ili s njima. Pluća i srce često ostaju neprepoznati i zanemareni organi u bolesnika s OI. U 
praćenju bolesnika s OI pozornost je uglavnom usredotočena na praćenje deformiteta dugih kostiju i kralježnice te neizravno na 
deformitete stijenke prsnog koša koji utječu na razvoj plućnih bolesti i bolesti dišnih putova. Plućni poremećaj često se zanemaruje 
sve dok problemi s disanjem ne postanu doista teški. U bolesnika s OI važna sastavnica je opstruktivna bolest pluća, poremećaj 
 disanja u snu te akutna i kronična infekcija koja je često povezana s nastankom bronhiektazija. Uz dišne komplikacije neki bolesnici 
s OI imaju ozbiljne srčanožilne probleme uključujući težak prolaps mitralnog zaliska, insufi cijenciju aortnog zaliska i dilataciju aorte, 
što zahtijeva operaciju srca. Dijagnostika i zbrinjavanje plućnih i srčanožilnih komplikacija prilično je teško u nekih bolesnika s OI. 
Kod svih bolesnika s OI važno je prepoznati i pratiti dišne i srčanožilne manifestacije kako bi se spriječilo daljnje napredovanje 
 komplikacija.
Ključne riječi: osteogenesis imperfecta; plućna bolest; plućna funkcija; plućne infekcije; srčanožilne manifestacije; prevencija
